IUHSA
RXRX icon

Itau Unibanco Holding S.A.’s Recursion Pharmaceuticals RXRX Stock Holding History

Itau Unibanco Holding S.A.’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,756
Closed -$13.2K – 415
2024
Q2 		$13.2K Buy
+1,756
New +$15.3K ﹤0.01% 265
2024
Q1 		– Sell
-3,161
Closed -$31.2K – 320
2023
Q4 		$31.2K Buy
+3,161
New +$22.5K ﹤0.01% 237
2023
Q2 		– Sell
-2,138
Closed -$14.3K – 599
2023
Q1 		$14.3K Hold
2,138
– – ﹤0.01% 427
2022
Q4 		$16.5K Buy
+2,138
New +$21K ﹤0.01% 409
2022
Q3 		– Sell
-4,678
Closed -$38K – 617
2022
Q2 		$38K Buy
4,678
+2,148
+85% +$14.4K ﹤0.01% 338
2022
Q1 		$18K Hold
2,530
– – ﹤0.01% 390
2021
Q4 		$44K Buy
+2,530
New +$47.6K ﹤0.01% 306

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Itau Unibanco Holding S.A.'s RXRX Position: Q3 2024 in Review

Itau Unibanco Holding S.A. sold out of Recursion Pharmaceuticals (RXRX) in Q3 2024, closing a stake of 1,756 shares — an estimated $13.2K sold.

Itau Unibanco Holding S.A. first reported a position in RXRX in Q4 2021 and held it in 7 quarters. The position peaked at $44K in Q4 2021. 267 funds tracked by Wall St. Rank hold RXRX as of Q3 2024.

  • Itau Unibanco Holding S.A. reported no remaining Recursion Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Itau Unibanco Holding S.A. sold 1,756 Recursion Pharmaceuticals shares in Q3 2024, an estimated $13.2K.
  • Itau Unibanco Holding S.A. first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • Itau Unibanco Holding S.A.'s Recursion Pharmaceuticals position peaked at $44K in Q4 2021.
  • 267 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2024.

Based on Itau Unibanco Holding S.A.'s 13F filing for Q3 2024, filed 14 Nov 2024.